Transient neonatal estrogen exposure to estrogen-deficient mice (aromatase knockout) reduces prostate weight and induces inflammation in late life

American Journal of Pathology

Volumn 168, Issue 6, 2006, Pages 1869-1878

  Bianco, Joseph John ^a   McPherson, Stephen John ^a   Wang, Hong ^a   Prins, Gail S ^b   Risbridger, Gail Petuna ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; AROMATASE; DIETHYLSTILBESTROL; ENDOCRINE DISRUPTOR; ESTROGEN; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EXPOSURE; DYSPLASIA; ESTROGEN DEFICIENCY; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; STATISTICAL ANALYSIS; STEREOLOGY; TESTOSTERONE BLOOD LEVEL; WILD TYPE;

EID: 33744744433     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050623     Document Type: Article

References (61)

1. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988, 122:552-562
2. Isaacs JT: Antagonistic effect of androgen on prostatic cell death. Prostate 1984, 5:545-557
3. Anderson KM, Liao S: Selective retention of dihydrotestosterone by prostatic nuclei. Nature 1968, 219:277-279
4. Bruchovsky N, Wilson JD: The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968, 243:2012-2021
5. Goto J, Fishman J: Participation of a nonenzymatic transformation in the biosynthesis of estrogens from androgens. Science 1977, 195:80-81
6. Tsugaya M, Harada N, Tozawa K, Yamada Y, Hayashi Y, Tanaka S, Maruyama K, Kohri K: Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer. Int J Urol 1996, 3:292-296
7. Stone NN, Laudone VP, Fair WR, Fishman J: Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol Res 1987, 15:165-167
8. Negri-Cesi P, Colciago A, Poletti A, Motta M: 5α-Reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. Prostate 1999, 41:224-232
9. Matzkin H, Soloway MS: Immunohistochemical evidence of the existence and localization of aromatase in human prostatic tissue. Prostate 1992, 21:309-314
10. Kaburagi Y, Marino MB, Kirdani RY, Greco JP, Karr JP, Sandberg AA: The possibility of aromatization of androgen in human prostate. J Steroid Biochem 1987, 26:739-742
11. Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H: Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997, 31:118-124
12. Harada N, Utsumi T, Takagi Y: Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 1993, 90:11312-11316
13. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP: Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004, 89:2434-2441
14. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930
15. Prins GS, Birch L: Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 1997, 138:1801-1809
16. Huhtaniemi IT, Warren DD, Catt KJ: Comparison of oestrogen and GnRH agonist analogue-induced inhibition of the pituitary-testicular function in rat. Acta Endocrinol (Copenh) 1983, 103:163-171
17. Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA: Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J Urol 1980, 124:232-236
18. Bianco JJ, Handelsman DJ, Pedersen JS, Risbridger GP: Direct response of the murine prostate gland and seminal vesicles to estradiol. Endocrinology 2002, 143:4922-4933
19. Fisher CR, Graves KH, Parlow AF, Simpson ER: Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998, 95:6965-6970
20. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP: Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001, 142:2458-2467
21. Prins GS, Woodham C, Lepinske M, Birch L: Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 1993, 132:2387-2398
22. Prins GS: Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992, 130:3703-3714
23. Rajfer J, Coffey DS: Sex steroid imprinting of the immature prostate. Long-term effects. Invest Urol 1978, 16:186-190
24. Naslund MJ, Coffey DS: The differential effects of neonatal androgen, estrogen and progesterone on adult rat prostate growth. J Urol 1986, 136:1136-1140
25. Naslund MJ, Strandberg JD, Coffey DS: The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988, 140:1049-1053
26. Rajfer J, Coffey DS: Effects of neonatal steroids on male sex tissues. Invest Urol 1979, 17:3-8
27. Prins GS, Birch L: The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 1995, 136:1303-1314
28. Woodham C, Birch L, Prins GS: Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology 2003, 144:4841-4850
29. Santti R, Newbold RR, Pylkkanen MS, McLachlan JA: Developmental estrogenization and prostatic neoplasia. Prostate 1994, 24:67-78
30. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS: Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 2001, 61:6089-6097
31. Pylkkanen L, Santti R, Newbold R, McLachlan JA: Regional differences in the prostate of the neonatally estrogenized mouse. Prostate 1991, 18:117-129
32. Pylkkanen L, Makela S, Valve E, Harkonen P, Toikkanen S, Santti R: Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice. J Urol 1993, 149:1593-1601
33. Gilleran JP, Putz O, DeJong M, DeJong S, Birch L, Pu Y, Huang L, Prins GS: The role of prolactin in the prostatic inflammatory response to neonatal estrogen. Endocrinology 2003, 144:2046-2054
34. De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999, 155:1985-1992
35. Putzi MJ, De Marzo AM: Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000, 56:828-832
36. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM: Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003, 162:1529-1537
37. McNeal JE, Bostwick DG: Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986, 17:64-71
38. McNeal JE: Significance of duct-acinar dysplasia in prostatic carcinogenesis. Urology 1989, 34:9-15
39. McNeal JE, Villers A, Redwine EA, Freiha FS, Stamey TA: Microcarcinoma in the prostate: its association with duct-acinar dysplasia. Hum Pathol 1991, 22:644-652
40. Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987, 59:788-794
41. Brawer MK: Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol 1992, 23:242-248
42. Robertson KM, O'Donnell L, Simpson ER, Jones ME: The phenotype of the aromatase knockout mouse reveals dietary phytoestrogens impact significantly on testis function. Endocrinology 2002, 143:2913-2921
43. Meachem SJ, McLachlan RI, de Kretser DM, Robertson DM, Wreford NG: Neonatal exposure of rats to recombinant follicle stimulating hormone increases adult Sertoli and spermatogenic cell numbers. Biol Reprod 1996, 54:36-44
44. Singh J, Zhu Q, Handelsman DJ: Stereological evaluation of mouse prostate development. J Androl 1999, 20:251-258
45. Risbridger GP, Wang H, Frydenberg M, Cunha G: The metaplastic effects of estrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. Endocrinology 2001, 142:2443-2450
46. Griffiths K: Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate 2000, 45:87-100
47. Wang W, Bergh A, Damber JE: Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004, 61:60-72
48. Gray A, Feldman HA, McKinlay JB, Longcope C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991, 73:1016-1025
49. Deslypere JP, Vermeulen A: Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984, 59:955-962
50. Baker HW, Burger HG, de Kretser DM, Hudson B, O'Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie GC: Changes in the pituitary-testicular system with age. Clin Endocrinol (Oxf) 1976, 5:349-372
51. Krieg M, Nass R, Tunn S: Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993, 77:375-381
52. Krieg M, Weisser H, Tunn S: Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Mol Biol 1995, 53:395-400
53. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ: A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995, 26:40-49
54. Seppelt U: Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy. J Clin Endocrinol Metab 1978, 47:1230-1235
55. Shibata A, Minn AY: Perinatal sex hormones and risk of breast and prostate cancers in adulthood. Epidemiol Rev 2000, 22:239-248
56. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991, 145:405-409
57. Prins GS: Developmental estrogenization of the prostate gland. Prostate Basic and Clinical Aspects. Edited by R Naz. New York, CRC press, 1997, pp 245-263
58. Arai Y, Mori T, Suzuki Y, Bern HA: Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. International Review of Cytology. Edited by GH Bourne, JF Danielle. New York, Academic Press, Inc., 1983, pp 235-268
59. Cunha GR, Hayward SW, Dahiya R, Foster BA: Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat 1996, 155:63-72
60. Chang W, Wilson M, Birch L, Prins G: Neonatal estrogen stimulates proliferation of periductal fibroblasts and alters the extracellular matrix composition in the rat prostate. Endocrinology 1999, 140:405-415
61. Stoker TE, Robinette CL, Cooper RL: Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes. Reprod Toxicol 1999, 13:463-472